目的 通過(guò)觀察注射用丹參多酚酸對(duì)復(fù)發(fā)緩解型多發(fā)性硬化（RRMS）的療效，檢測(cè)血清基質(zhì)金屬蛋白酶9（MMP-9）用藥前后含量變化，分析MMP-9與擴(kuò)展功能障礙狀態(tài)量表（EDSS）評(píng)分、日常生活能力量表（ADL）評(píng)分的相關(guān)性，評(píng)估注射用丹參多酚酸對(duì)RRMS急性期患者療效。方法 隨機(jī)將40例RRMS患者分為兩組，各20例。對(duì)照組采用糖皮質(zhì)激素與神經(jīng)營(yíng)養(yǎng)藥物，觀察組在此基礎(chǔ)上加用注射用丹參多酚酸，每日1次。兩組均治療14 d。觀察兩組治療前、用藥14 d后血清MMP-9水平及治療前、治療14、28 d后EDSS及ADL評(píng)分。結(jié)果 兩組患者治療14 d后血清MMP-9水平均增高，觀察組患者M(jìn)MP-9水平增高幅度明顯低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者治療14 d后及治療后28 d EDSS評(píng)分均明顯下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組EDSS評(píng)分降低的程度大于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者治療14 d后及治療后28 d ADL評(píng)分均較治療前升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組ADL評(píng)分高于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 注射用丹參多酚酸可以降低RRMS患者M(jìn)MP-9水平，改善臨床癥狀，提高生存質(zhì)量，用藥后安全有效，無(wú)嚴(yán)重不良反應(yīng)。

Objective Clinical observe the curative effect on multiple sclerosis by Salvianolic Acids for Injection, by detecting the content of MMP-9 in the serum before and after taking the medicine,analyzing the correlation between MMP-9 and EDSS/ADL grade, assess the curative effect on patients with acute phase of RRMS that injected with Salvianolic Acids for Injection. Method (1) Case collect:randomly divide the 40 MS into observation group and control group, 20 cases in each group. (2)Test index:test serum MMP-9 before the first treatment, and after 14 days of initial treatment, review serum MMP-9, testing company test serum MMP-9. (3) Assess EDSS grade and ADL grade before treatment, 14 days after treatment and 28 days after treatment. (4) Dosage regimen:the control group using glucocorticoid and neurotrophic drugs, the observation group on above basis, give Salvianolic Acids for Injection as treatment, once a day. Both groups were treated for 14 days. Results The levels of serum MMP-9 in both groups increased 14 days after treatment. The increase of serum MMP-9 in the observation group was significantly lower than that in the control group (P<0.05). The EDSS scores of the two groups decreased significantly after 14 days of treatment and 28 days of treatment, and there was a significant difference between the two groups before and after treatment (P<0.05), and the EDSS scores of the observation group were significantly lower than those of the control group (P<0.05). The ADL scores of the two groups after 14 days of treatment and 28 days of treatment were higher than those before treatment, and the difference between the two groups before and after treatment was statistically significant (P<0.05); and the ADL scores of the observation group were higher than those of the control group, the difference was statistically significant (P<0.05). Conclusion Salvianolic Acids for Injection can reduce the MMP-9 levels in multiple sclerosis patients, improve clinical symptoms, improve life quality of patients, the medication is safe and effective, no serious adverse reactions.